s0122319
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- COAGULATION+0.400
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- ALLOGRAFT_REJECTION+0.300
- ANGIOGENESIS+0.300
- APICAL_SURFACE+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
Top 10 suppressed
- ADIPOGENESIS-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- FATTY_ACID_METABOLISM-0.300
- NOTCH_SIGNALING-0.300
- PEROXISOME-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- UV_RESPONSE_UP-0.200
- BILE_ACID_METABOLISM-0.100
- CHOLESTEROL_HOMEOSTASIS-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2304 | Med | Medulloblastoma | 0.820 |
| 2 | BS_15ETQ0E4 | ATRT | — | 0.817 |
| 3 | c56e13bb-f1b0-4ee3-85c1-807c7c3bcef9 | — | — | 0.813 |
| 4 | R385 | — | — | 0.804 |
| 5 | TCGA-49-4487-01A-21R-1858-07 | — | cohortMD2 | 0.798 |
| 6 | BS_AHEFXG7W | Med | Medulloblastoma | 0.790 |
| 7 | ERR2278857 | — | — | 0.785 |
| 8 | DRR168533 | — | — | 0.784 |
| 9 | R263 | — | — | 0.783 |
| 10 | MNG539 | — | — | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |